Legacy Wealth Management (Idaho)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-260
Closed -$31.7K – 1070
2025
Q4
$31.7K Buy
+260
New +$29.8K 0.02% 274

Other funds holding XBI

Legacy Wealth Management (Idaho)'s XBI Position: Q1 2026 in Review

Legacy Wealth Management (Idaho) sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 260 shares — an estimated $31.7K sold.

Legacy Wealth Management (Idaho) first reported a position in XBI in Q4 2025 and held it in 1 quarter. The position peaked at $31.7K in Q4 2025. 816 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Legacy Wealth Management (Idaho) reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
  • Legacy Wealth Management (Idaho) sold 260 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $31.7K.
  • Legacy Wealth Management (Idaho) first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and held it in 1 quarter.
  • Legacy Wealth Management (Idaho)'s State Street SPDR S&P Biotech ETF position peaked at $31.7K in Q4 2025.
  • 816 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Legacy Wealth Management (Idaho)'s 13F filing for Q1 2026, filed 7 May 2026.